Research in contextEvidence before this studyWe searched PubMed for articles published in English up to March 2020 with the terms "Alzheimer\'s biomarkers", "peripheral biomarkers", "saliva proteins", "saliva function", "preclinical Alzheimer", "Alzheimer prediction", "lactoferrin", "infections", "immune system", among others. All these studies conclude the urgent need for the development of early diagnostic methods that can accurately detect and diagnose Alzheimer\'s disease (AD). In recent years, there have been intensified efforts in the search for minimum or non-invasive peripheral markers, such as blood, or saliva, for the early diagnosis of AD. Findings have shown the association between AD and immune system, including virus, bacteria and yeast infections, which is associated with an increased inflammatory response. Moreover, it has been proposed that brain infections may be involved in the development of AD. The dissemination of oral microorganisms to the brain is controlled by antimicrobial peptides, as part of the innate immune system. In the last decade, several studies have explored the role of these antimicrobial peptides as potential biomarkers for AD. In 2017, we showed that salivary lactoferrin (Lf) discriminates between patients with mild cognitive impairment (MCI) and AD from control subjects.Added value of this studyThis is, to our knowledge, the first study to assess the excellent diagnostic performance and specificity of a saliva-based single biomarker to detect prodromal AD and AD dementia based on their amyloid-PET biomarker profile. Moreover, an independent cross-sectional independent study was able to replicate the diagnostic performance of saliva Lf concentrations. The results shown that salivary Lf levels are decreased in AD and are associated with amyloid-PET imaging profile even in prodromal disease. The fact that salivary Lf levels are unchanged in other degenerative dementia, such as frontotemporal dementia (FTD), supports the possible use of salivary Lf in the differential diagnosis of AD vs other dementias.Implications of all the available evidenceThe most clinically relevant finding of this study is the excellent diagnostic performance of salivary Lf to detect prodromal AD and AD dementia distinguishing from other dementia as FTD, with sensitivities and specificities over 87% and 91%, respectively. Our results support the use of salivary Lf as an easily accessible, non-invasive and cost-effective biomarker for early AD diagnosis. Earlier and more reliable diagnoses for AD will have a direct impact on the design of future clinical trials. Finally, this study also propose that salivary Lf represents one of the main/first defence line against pathogens, hence low Lf levels in saliva may exacerbate AD risk.Alt-text: Unlabelled box

1. Introduction {#sec0004}
===============

Alzheimer\'s disease (AD) is one of the most devastating neurodegenerative disorders representing a major public health concern with more than 30 million people affected worldwide. The cause of the disease is still unknown but the most accepted hypothesis states that amyloid-β (Aβ) accumulation in the brain could initially trigger the pathological cascade.

Accumulated evidence suggests that bacterial and viral infections may be implicated in AD pathogenesis [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005]. In the cascade of events preceding AD, oral and gastrointestinal microorganisms may play a role \[[@bib0006],[@bib0007]\], and different types of microbes have shown to stimulate Aβ aggregation and deposition \[[@bib0008],[@bib0009]\]. Therefore, it may exist an interplay between genetic and environmental risk factors including toxins and/or bacterial, viral and fungal pathogens in the sporadic form of late-onset AD reflecting its complex and multifactorial aetiology [@bib0010].

The question of whether oral infections could be considered as a risk factor for AD has generated considerable research in recent years. Antimicrobial proteins and peptides (APPs), also called host defence agents, are the primary effector molecules of innate immunity. A novel role for APPs has been proposed in AD pathology. The emerging role of microbes and innate immune pathways in AD pathology also suggests that APPs may be considered for early therapeutic interventions in future clinical trials. Pathogen-targeting agents and brain infections markers are involved in amyloid aggregation, reinforcing the possible relationship between AD and brain infections \[[@bib0011],[@bib0012]\].

Biomarkers reflecting innate immune system integrity could therefore be useful for both, accurate and early diagnosis, as well as disease prognosis. A promising biomarker candidate is lactoferrin (Lf), an iron-binding protein belonging to the transferrin family and expressed in all body fluids, particularly in exocrine fluids, tears or saliva [@bib0013]. Lf has a wide variety of physiological functions including, antioxidant activities, neuroprotective properties, regulation of the immune response, anti-inflammatory and anti-carcinogenic potential [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018]. In addition, Lf has been previously detected in senile plaques, neurofibrillary tangles [@bib0019] and microglia from AD brains [@bib0020]. Since Lf is one of the major antimicrobial peptides in saliva, it further represents an important defensive element by inducing a broad-spectrum of antimicrobial effects against bacteria, fungi, protozoa, viruses and yeasts [@bib0021]. The antimicrobial effects of Lf are conferred by its highly positive charged N-terminal region [@bib0022]. These functions are maintained by its hydrolysis products, a number of Lf-derived peptides that by retaining the cationic N-terminal region of the native protein also retain many of the Lf activities and in some cases, they can be even more potent than the parent protein \[[@bib0021],[@bib0023]\].

We have previously shown decreased Lf levels in saliva samples from mild cognitive impairment (MCI) and AD patients compared with normal elderly subjects [@bib0024]. In the present study, we have evaluated the diagnostic utility of salivary Lf in a well-characterised cohort of AD and frontotemporal dementia (FTD) patients, as well as in normal elderly subjects. Results have been lately validated in an independent cohort of MCI patients and healthy controls. In order to assess the salivary Lf specificity and its relationship with the pathophysiological process of AD, only participants with known amyloid-Positron-Emission Tomography (PET) status were included.

2. Materials and methods {#sec0005}
========================

2.1. Human donors {#sec0006}
-----------------

Two prospective, cross-sectional, multicenter studies were examined divided in two different cohorts. Study participants from cohort 1 were consecutively enrolled between 2014 and 2018 from the 12 de Octubre University Hospital Neurology Service in Madrid (Spain) and Pablo de Olavide University in Sevilla (Spain). Study participants from cohort 2 were consecutively enrolled between June 2017 and December 2018 as part of the Atherobrain - Heart to Head (H2H) project. Data from both cohorts were analysed in 2018.

All participants were classified using established diagnostic criteria into those with MCI or dementia including AD [@bib0025], [@bib0026], [@bib0027] and FTD [@bib0028], and those without clinical signs of cognitive impairment classified as healthy controls. Diagnosis was based on detailed clinical assessment, neuropsychological study, neuroimaging and amyloid-Positron-Emission Tomography (PET) scan results. Global cognition was assessed using the Mini Mental State Examination (MMSE) [@bib0029]. Functional impairment was measured via the Clinical Dementia Rating (CDR) score [@bib0030]. All patients had to fulfil diagnosis criteria. Exclusion criteria were evidences of concomitant psychiatric, neurological or non-neurological medical conditions or medications that could affect cognition. Inclusion criteria for controls were age over 60, MMSE score over 27, no history or clinical signs of neurological or psychiatric disease, and preservation of social and functional abilities.

116 participants composed cohort 1: 52 out of 116 were healthy asymptomatic subjects considered as controls, 21 out of 116 were diagnosed as MCI due to AD, 25 out of 116 were AD dementia and 18 out of 116 were FTD. 142 participants composed cohort 2: 74 out of 142 were cognitively normal subjects, and 68 out of 142 patients were clinically diagnosed as MCI. From the MCI group, 39 subjects were diagnosed as prodromal AD and the others as MCI not due to AD. Of all control participants 4 subjects from cohort 1 and 4 subjects from cohort 2 had a positive amyloid-PET (PET^+^) result. These participants were included in the demographic description to show the population heterogeneity, but not in the statistical analysis due to the small number of cases.

Approval of the study was obtained from the Research Ethics Committee of each entity, and all participants provided written consent to take part.

2.2. Saliva samples {#sec0007}
-------------------

Saliva samples were collected and processed from all subjects as described previously [@bib0024]. Briefly, an unstimulated saliva sample (about 0•5--1 ml) was obtained by collection into a 2% sodium azide solution pre-coated sterile plastic tube. Samples were collected at a consistent time of day to avoid circadian effects and were kept on ice during and following collection. After collection was completed, saliva samples were pre-cleared by a low spin at 600 × g for 10 min at 4 °C. 0•5 ml aliquots were stored at −80 °C after treatment with Protease Inhibitor Cocktail (Roche).

2.3. DNA purification and *APOE* genotyping {#sec0008}
-------------------------------------------

Genomic DNA was extracted from peripheral blood using QIAmp DNA Blood Mini Kit (Qiagen), according to the manufacturer instructions. Human *APOE* C112R and R158C polymorphisms were detected to identify the *APOE* ε2, ε3 and ε4 alleles, using LightCycler 480 II Instruments Kit (Roche Diagnostics) following manufacturer instructions.

2.4. ELISA {#sec0009}
----------

Levels of Lf in saliva samples were determined using the Lf human ELISA kit (ab200015, Abcam) according to manufacturer\'s instructions.

2.5. Amyloid-PET scan {#sec0010}
---------------------

Amyloid-PET scan was carried out in all participants. \[^18^F\]-florbetapir (Amyvid, Eli Lilly & Co. and Avid Radiopharmaceuticals Inc.), \[^18^F\]-florbetaben (Neuraceq, Pyramidal Imaging Limited), and \[^18^F\]-flutemetamol (Vizamyl, GE Healthcare) PET scans were performed at the 12 de Octubre University Hospital, Pablo de Olavide University and the National Centre for Cardiovascular Research (CNIC), as previously described [@bib0031], [@bib0032], [@bib0033]. Images were generated 90--110 min after \[^18^F\]‐florbetaben intravenous injection (mean dose, 300 MBq) or 90 min after \[^18^F\]-flutemetamol intravenous injection (mean dose, 185 MBq; 20 min acquisition) or \[^18^F\]-florbetapir intravenous injection (mean dose, 370 MBq; 20 min acquisition). Images were analysed with the Syngo PET 6•7•2 (Siemens Healthcare) software and IntelliSpace Portal (Philips Healthcare) software. PET scans were analysed using standardised criteria [@bib0034].

2.6. Statistical analysis {#sec0011}
-------------------------

We compared salivary Lf levels between the different diagnostic groups according to the amyloid-PET imaging biomarker profile. Numerical data are shown as mean ± standard deviation (SD) and categorical data as a percentage. To compare demographic, clinical, and salivary Lf data within cohorts, we used one-way ANOVA followed by Bonferroni correction or the nonparametric Kruskal-Wallis rank test and non-parametric pairwise comparisons followed by Bonferroni correction, according to sample distribution. Student\'s *t*-test was used for single pairwise comparisons. Fisher\'s exact test was used to compare the distribution of categorical data across groups. Correlations between biomarker and subject\'s features were assessed using Spearman rank correlation. In addition, receiver operating characteristic (ROC) curve using binomial logistic regression analysis in the discovery cohort 1 and the validation cohort 2 were used to determine the diagnostic accuracy of salivary Lf to differentiate between diagnostic groups and amyloid-PET status. The optimal cut-off point was determined by Youden\'s J index (*J* = sensitivity + specificity -- 1) by analysing the cohort 1. Sensitivity, specificity and area under the curve (AUC) were calculated in all cases. Statistical significance was set at *p* \< 0•05. Statistical analysis was performed using GraphPad Prism version 6•00 and STATA/IC 14•2 for Windows.

3. Results {#sec0012}
==========

3.1. Demographics {#sec0013}
-----------------

Demographic and clinical data of participants are shown in [Table 1](#tbl0001){ref-type="table"} (cohort 1) and [Table 2](#tbl0002){ref-type="table"} (cohort 2). In cohort 1 ([Table 1](#tbl0001){ref-type="table"}, *n* = 116 subjects), 50 out of 116 participants were positive for amyloid--PET (PET^+^) (43•1% prevalence) and 66 out of 116 were negative (PET^−^; 56% prevalence). From the PET^+^ group, 21 out of 50 were clinically diagnosed with MCI due to AD (MCI-PET^+^; 42% prevalence), and 25 out of 50 were diagnosed with AD dementia (AD-PET^+^; 50% prevalence). Four controls showed a PET^+^ status (Control-PET^+^), representing the 7•7% of all controls in cohort 1. About the PET^−^ subjects, 18 out of 66 were clinically diagnosed with FTD (FTD-PET^−^; 27•3% prevalence) and 48 out of 66 were found asymptomatic (Control-PET^−^; 72•7% prevalence).Table 1Demographic and clinical data of the participants in cohort 1.Table 1**Cohort 1CharacteristicControl-PET^−^Control-PET^+^MCI-PET^+^AD-PET^+^FTD-PET^−^*p*-value**(*n* = 48)(*n* = 4)(*n* = 21)(*n* = 25)(*n* = 18)\#Age, mean (SD), y66•9 (5•9)75•9 (3•6)68•8 (7•5)67•2 (9•2)73•8 (5•6)[a](#tb1fn7){ref-type="table-fn"}^,^[b](#tb1fn1){ref-type="table-fn"}\<0•01Female sex, n (%)33 (68•8)2 (50•0)8 (38•1)12 (48•0)11 (61•1)nsDisease duration, mean (SD), y----2•8 (1•5)4•0 (1•7)3•7 (1•7)nsMMSE score, mean (SD)29•0 (1•1)28•0 (0•8)25•1 (2•3)[d](#tb1fn3){ref-type="table-fn"}19•2 (6•0)[c](#tb1fn2){ref-type="table-fn"}^,^[d](#tb1fn3){ref-type="table-fn"}20•5 (9•2)[d](#tb1fn3){ref-type="table-fn"}\<0•0001CDR, mean (SD)000•51•3 (0·5)0•9 (0•7)NA*APOE* ε4 carrier, No. (%)6 (17•1)[a](#tb1fn7){ref-type="table-fn"}^,^[c](#tb1fn2){ref-type="table-fn"}--14 (66•7)12 (48•0)1 (5•6)[c](#tb1fn2){ref-type="table-fn"}^,^[e](#tb1fn4){ref-type="table-fn"}\<0•0001Saliva Lf, µg/ml (SD)7•7 (2•4)9•8 (5•4)3•8 (2•0)[d](#tb1fn3){ref-type="table-fn"}^,^[g](#tb1fn6){ref-type="table-fn"}3•6 (1•5)[d](#tb1fn3){ref-type="table-fn"}^,^[g](#tb1fn6){ref-type="table-fn"}9•7 (2•9)[f](#tb1fn5){ref-type="table-fn"}\<0•0001[^1][^2][^3][^4][^5][^6][^7][^8][^9]Table 2Demographic and clinical data of the participants in cohort 2.Table 2**Cohort 2CharacteristicControl-PET^−^Control-PET^+^MCI-PET^−^MCI-PET^+^*p*-value**(*n* = 70)(*n* = 4)(*n* = 29)(*n* = 39)\#Age, mean (SD), y71•1 (5•7)70•3 (4•5)75•3 (5•9)74•4 (5•3)nsFemale sex, n (%)43 (62•3)2 (50•0)20 (69•0)26 (66•7)nsDisease duration, mean (SD), y----2•6 (1•7)3•3 (1•8)nsMMSE score, mean (SD)28•6 (1•1)29•5 (0•6)25•1 (2•2)[c](#tb2fn4){ref-type="table-fn"}24•3 (2•1)[c](#tb2fn4){ref-type="table-fn"}\< 0•0001CDR, mean (SD)000·50·5NA*APOE* ε4 carrier, No. (%)4 (5•7)07 (24•1)[a](#tb2fn1){ref-type="table-fn"}12 (30•8)[b](#tb2fn2){ref-type="table-fn"}\< 0•001Saliva Lf, µg/ml (SD)9•2 (2•9)[d](#tb2fn3){ref-type="table-fn"}4•6 (1•3)7•4 (4•6)[d](#tb2fn3){ref-type="table-fn"}3•5 (2•5)\< 0•0001[^10][^11][^12][^13][^14][^15]

In the independent validation cohort (cohort 2; [Table 2](#tbl0002){ref-type="table"}, *n* = 142 subjects), 43 out of 142 participants were PET^+^ (30•3% prevalence) and 99 out of 142 were PET^−^; 73•9% prevalence). All PET^+^ subjects received the diagnosis of MCI due to AD except for 4 participants, which stayed cognitively healthy. This group represented the 5•4% of all controls in cohort 2. From the PET^−^ group, 29 out of 99 were diagnosed with MCI probably not due to AD (MCI-PET^−^; 29•3% prevalence) and 70 out of 99 were found asymptomatic (70•7% prevalence).

No significant sex differences were found between groups. Mean age was statistically similar in all groups except for the FTD group from cohort 1, which was higher ([Table 1](#tbl0001){ref-type="table"}). All patients showed lower MMSE scores than controls, specially AD and FTD groups. As expected, *APOE* ε4 genotype was significantly higher in MCI-PET^+^ group and AD compared with asymptomatic subjects and FTD patients, according to previous publications [@bib0035], [@bib0036].

In cohort 2, mean age was statistically similar in all groups. MCI patients showed lower MMSE scores than controls. Prevalence of *APOE* ε4 genotype was significantly higher in MCI-PET^+^ group and AD compared with asymptomatic subjects.

MCI-PET^−^ group also showed a significantly higher prevalence of *APOE* ε4 genotype compared with the healthy control group.

3.2. Salivary LF levels across diagnostic groups {#sec0014}
------------------------------------------------

In cohort 1, salivary Lf levels were significantly lower in MCI-PET^+^ (3•8 ± 2 µg/ml) and AD (3•6 ± 1•5 µg/ml) groups compared with cognitively normal elderly subjects (7•7 ± 2•4 µg/ml; *p* \< 0•0001, Bonferroni; [Fig. 1](#fig0001){ref-type="fig"}a), and FTD patients (mean 9•7 ± 2•9 µg/ml; *p* \< 0•0001, Bonferroni; [Fig. 1](#fig0001){ref-type="fig"}a). Lf levels in FTD group were slightly increased compared with controls (*p* \< 0•05, Bonferroni) but the difference was much more relevant when comparing with MCI-PET^+^ and AD-PET^+^groups. No significant differences in salivary Lf levels were found between MCI-PET^+^ and AD patients ([Table 1](#tbl0001){ref-type="table"}, [Fig. 1](#fig0001){ref-type="fig"}a). Regarding the control-PET^+^ group, levels of Lf were inconsistent, showing values of 16•0, 12•6, 6•0 and 4•6 µg/ml.Fig. 1**Salivary Lf levels by clinical diagnosis and amyloid-PET biomarker profile.** Box and whisker plots showing salivary Lf levels across diagnostic groups within (**a**) cohort 1, and (**b**) cohort 2. Boxes represent the 25th, 50th and 75th data percentiles. Whiskers represent the lowest and highest data. Scatter plots showing salivary Lf levels in (**c**) all subjects grouped as negative (*n* = 165) and positive (*n* = 85) amyloid-PET biomarker profile (excluding the control-PET^+^ subjects), and (**d**) in patients (excluding healthy asymptomatic controls) grouped as negative (*n* = 47) and positive (*n* = 85) amyloid-PET biomarker profile. Differences between groups were assessed using Kruskal-Wallis test or one-way ANOVA followed by Bonferroni and Student\'s *t*-test. \**p* \< 0•05; \*\*\*\**p* \< 0•0001. Lf, lactoferrin; MCI, Mild cognitive impairment; AD, Alzheimer´s disease dementia; FTD, frontotemporal dementia; PET^+^, positive amyloid-PET scan; PET^−^, negative amyloid-PET scan.Fig 1

In cohort 2, saliva Lf levels were significantly lower in MCI-PET^+^ (3•5 ± 2•5 µg/ml) group compared with healthy controls (9•2 ± 2•9 µg/ml; *p* \< 0•0001, Bonferroni), and MCI-PET^−^ (mean 7•4 ± 4•6 µg/ml; *p* \< 0•0001, Bonferroni; [Table 2](#tbl0002){ref-type="table"}, [Fig. 1](#fig0001){ref-type="fig"}b). No differences in salivary Lf levels were found between control and MCI-PET^−^ groups. Regarding the control-PET^+^ group, levels of Lf tended to be down-regulated, and the 4 subjects showed values of 6•5, 4•4, 3•8 and 3•7 µg/ml.

Cohort 1 and cohort 2 combination (*n* = 250, excluding the 8 control-PET^+^ subjects), resulted in 165 out of 250 PET^−^ and 85 out of 250 PET^+^ subjects. Salivary Lf levels were significantly higher in the PET^−^ group (8•5 ± 3•2 µg/ml) compared with the PET^+^ group (3•6 ± 2•1 µg/ml; *p* \< 0•0001, Student\'t; [Fig. 1](#fig0001){ref-type="fig"}c). By excluding the control group, analysis also reported significant differences in salivary Lf levels between PET^−^, covering FTD and some MCI patients (8•3 ± 4•2 µg/ml), and PET^+^patients (*p* \< 0•0001, Student\'t; [Fig. 1](#fig0001){ref-type="fig"}d).

3.3. Correlations between salivary LF and demographic, clinical, and *APOE* genotype {#sec0015}
------------------------------------------------------------------------------------

We then investigated correlations between salivary Lf concentrations and clinical and demographic data, including age, MMSE score, disease duration and CDR, in separated groups within cohorts and by combinination of all of them. We also assessed the effects of *APOE* ε4 genotype in Lf levels. We found that higher salivary Lf levels were associated with higher MMSE scores (*r* = 0•69; *p* \< 0•01) and lower CDR scores (*r* = −0•59; *p* \< 0•01) in the FTD group ([Table 3](#tbl0003){ref-type="table"}). No correlations were found either with MMSE or CDR in the other groups in cohort 1 and 2, nor between salivary Lf levels and age or disease duration in the combined or in the separated groups.Table 3Spearman rank correlations of saliva Lf levels with MMSE and CDR in the whole dataset and diagnostic groups.Table 3**Cohort 1Correlation coefficientWhole datasetControlMCI/ADFTD**MMSE0•42[a](#tb3fn1){ref-type="table-fn"}0•04−0•030•69[b](#tb3fn2){ref-type="table-fn"}CDR−0•49[a](#tb3fn1){ref-type="table-fn"}--−0•19−0•59[b](#tb3fn2){ref-type="table-fn"}**Cohort 2Correlation coefficientWhole datasetControlMCI-PET^+^MCI-PET^−^**MMSE0•40[a](#tb3fn1){ref-type="table-fn"}0•20−0•27−0•04CDR−0•53[a](#tb3fn1){ref-type="table-fn"}------[^16][^17][^18][^19]

According to *APOE* genotype, no differences were found between Lf levels in saliva in *APOE* ε4 carriers compared with *APOE* ε2 and ε3 carriers within the diagnostic groups, suggesting that the *APOE* ε4 genotype is not related to salivary Lf levels.

3.4. Diagnostic value for LF {#sec0016}
----------------------------

Lf results were analysed using logistic regression models in cohort 1 and the validation cohort 2, excluding control PET^−^ from both cohorts. Using the Youden\'s index, we found that the optimal cut-off point to differentiate salivary Lf from MCI/AD-PET^+^patients and control-PET^−^ group was 5•63 µg/ml in cohort 1. At this cut-off point, specificity and sensitivity were estimated in 91•67% and 86•96%, respectively. The obtained area under the curve (AUC) was 0•952 (95% CI, 0•911 - 0•992) ([Table 4](#tbl0004){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}a). Using the same cut-off point, the obtained sensitivity and specificity differentiating MCI/AD-PET^+^ from FTD-PET^−^ patients were 86•96% and 88•89%, respectively. The AUC was 0•97 (95% CI, 0•924 - 1•00) ([Table 4](#tbl0004){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}b). Combining Lf levels from all subjects in cohort 1 grouped as PET^−^ and PET^+^ and keeping the cut-off point of 5•63 µg/ml, we obtained 86•96% sensitivity and 90•91% specificity ([Table 4](#tbl0004){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}c).Table 4Sensibility and specificity of salivary Lf in cohort 1 and validation cohort 2.Table 4**Cohort 1Validation cohort 2(*n*** **=** **112)(*n*** **=** **138)MCI/AD-PET^+^MCI/AD-PET^+^MCI/AD-PET^+^MCI-PET^+^MCI-PET^+^MCI-PET^+^vs. Controlvs. FTD-PET^−^vs. PET^−^vs. Controlvs. MCI-PET^−^vs. PET^−^**AUC0•950•970•960•930•760•88(95% CI)(0•911, 0•992)(0•924, 1)(0•922, 0•990)(0•876, 0•989)(0•637, 0•878)(0•817, 0•945)Sensitivity,%86•9686•9686•9687•0584•6282•05Specificity,%91•6788•8990•9192•8658•6282•83Accuracy,%89•3687•5089•2988 0•9973•5382•61Cut-off, µg/ml5•635•635•635•635•635•63[^20]Fig. 2**Receiver operating characteristic (ROC) analysis of salivary Lf in cohort 1 and cohort 2.** ROC curves and their corresponding areas under the curve (AUCs) to differentiate between (**a**) MCI/AD-PET^+^ patients and control-PET^−^, (**b**) MCI/AD-PET^+^ and MCI/FTD-PET^−^ patients, and (**c**) MCI/AD-PET^+^ and PET^--^ in cohort 1. ROC curves and their corresponding areas under the curve (AUCs) to differentiate between (**d**) MCI-PET^+^ patients and control-PET^−^, (**e**) MCI-PET^+^ and MCI-PET^−^ patients, and (**f**) MCI-PET^+^ and PET^--^ in cohort 2. ROC; receiver operating characteristic; MCI, mild cognitive impairment; AD, Alzheimer\'s disease dementia; FTD, frontotemporal dementia; PET^+^, positive amyloid-PET scan; PET^−^, negative amyloid-PET scan.Fig 2

In the validation cohort 2 analyses, the cut-off estimated from cohort 1 was replicated. The AUC to differentiate MCI-PET^+^ patients from control-PET^−^ was 0•93 (95% CI, 0•876 - 0•989), with 92•86% specificity and 87•05% sensitivity ([Table 4](#tbl0004){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}d). Both, the accuracy and specificity to differentiate MCI-PET^+^ from MCI-PET^−^ groups were lower ([Table 4](#tbl0004){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}e), due to the higher variability in the salivary Lf levels observed in the MCI-PET^−^ group. That could be explained because MCI patients with negative amyloid PET comprise a heterogeneous group with different and/or mixed non-amyloid aetiologies. Combining Lf levels from all subjects in cohort 2 grouped as PET^−^ and MCI-PET^+^ and keeping the cut-off point of 5•63 µg/ml from cohort 1, we obtained 82.05% sensitivity and 82•83% specificity with an AUC of 0•88 (95% CI, 0•817 - 0•945) ([Table 4](#tbl0004){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}f). Overall, these results revealed that salivary Lf is able to differentiate between subjects with positive and negative cerebral amyloidosis with high accuracy.

4. Discussion {#sec0017}
=============

Here we show that reduced salivary Lf levels seem to be specific to AD as such observation is not extended to healthy elderly controls or FTD, as example of different dementia, neither to advanced age healthy controls. We demonstrate that reduced Lf levels are associated to positive amyloid PET result, one of the available pathophysiological validated AD biomarkers. These findings agree with our previously reported study in which reduced salivary Lf levels were found in amnesic MCI and AD patients [@bib0024].

Brain Aβ aggregation is thought to play a major role in AD aetiology, but the amyloid cascade hypothesis cannot explain the pathological process of AD by itself. In 2016, a hypothesis postulated that brain infections might play an initial role in amyloid plaque formation and the development of AD [@bib0037], proposing a potential novel role for APPs in AD pathophysiology [@bib0011]. These infections lead to persistent inflammatory stimuli altering the immune response [@bib0038]. Different lines of evidence suggest that AD-affected brains host virus, including herpes virus and hepatitis virus [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], and bacteria, including *Chlamydia, Borrelia spirochetes*, or *Helicobacter Pylori* [@bib0039]. Those bacterial and viral populations in the brain might induce Aβ aggregation, triggering the AD pathophysiological process [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0008], [@bib0009]. However, it remains unclear whether the entry of pathogens occurred at the onset of AD or it may be the consequence of a leaky blood brain barrier (BBB) induced by chronic infections-derived inflammatory processes or, ultimately, if it is secondary to AD itself. It is important to recognise that infections can occur decades before evident signs of dementia. In agreement with this hypothesis, a number of risk factors, including chronic infections, obesity, diabetes, depression and stress among others, are known to contribute down-regulating the innate immune system and thus increasing the risk for infections. On this regard, is interesting to mention the recent work carried out by Ilievski and colleagues in which they have found a connection between oral infection and the development of AD-like pathology [@bib0040]. The authors orally administered *Porphyromonas gingivalis* (Pg) and/or its product gingipain to 8-month-old C57/BL6 mice for 22 weeks. Then, they found hippocampal and cortical neuropathology including Aβ plaques, neurofibrillary tangle formation, astrogliosis and microgliosis in the treated mice, but not in the control group [@bib0040]. More recently, Dominy and colleagues demonstrated the presence of Pg DNA and gingipain antigens in brains from AD patients [@bib0041].

Oral homoeostasis is dependant upon saliva and its protein content. An alternative approach to understand the AD aetiopathogenesis has been recently reported: a potential microbial infection and innate immune origins for the disease [@bib0042]. This approach opened the way for a paradigm shift in studying a new "infection hypothesis," or perhaps more broadly, "innate immune system dysregulation hypothesis". It suggests the role of chronic infections in the development of AD, as well as a potential deregulation of the human innate immune response to these infections, as a plausible route for new investigations of the aetiology and pathophysiology of AD [@bib0043]. Although AD is a complex disease and microbial infection may not be the sole cause, this new paradigm may provide novel targets for the prevention and treatment of this devastating disease.

The dissemination of oral microorganisms in the brain is controlled by APPs, as part of the innate immune system. In the last decade, several studies have explored the role of these APPs as potential biomarkers for AD [@bib0011]. In 2017, we showed that salivary Lf levels, one of the major antimicrobial proteins in saliva, discriminates between patients with MCI and AD and control subjects [@bib0024]. Although Lf cleavage generates antimicrobial peptides, sometimes with higher antimicrobial capacity, the protein itself has antimicrobial effects as these properties are conferred by its highly positive charged N-terminal domain and this domain is retained by its generated peptides. These differences come from the observation of Lf-derived peptides exerted higher antibacterial capacity compared to native Lf. However, that was not the case of the antiviral capacity as several works demonstrated that mature protein has much more effect [@bib0021]. APPs are defensive agents constitutively expressed, but they can be modulated during inflammation or a microbial challenge, including chronic bacterial or viral infections. APPs have been studied for decades for their action against pathogens, and their immunostimulatory effects [@bib0023]. As part of the innate immune system, APPs are defensive peptides that enter the brain and efficiently target pathogens through synergistic pathways [@bib0011]. The normal production of APPs may be reduced because of a number of factors such as a weakened immune system or damaged defence cells. We then hypothesise that reduced levels of salivary Lf could reflect compromised immunity resulting in an enhanced risk of brain infections. Lf is known to be transferred from the sublingual mucosa to the brain [@bib0044]. In this context, favourable Lf effects on brain are expected, and they could be related to its antimicrobial capacity but also they may stimulate the non-amyloidogenic processing of APP and the α-secretase catalytic activity and expression in a mouse model of AD [@bib0045].

Human Lf exerts multifunctional effects displaying extensive antimicrobial, anti-inflammatory and immunomodulatory activities. Lf may deprive microorganisms such as bacteria, yeasts and parasites binding and sequestering iron, which is essential for their growth [@bib0046]. Lf has different iron binding statuses: the iron-free (apo) form, the native form, and the iron-saturated (holo) form. It has been shown that both, the apo-Lf form as well as the holo-Lf form mediate agglutination of microorganisms indicating that Lf possess strong iron-binding independent bacteriolytic properties [@bib0047]. Moreover, previous studies also demonstrated that Lf showed antioxidant effects depending on its iron binding status [@bib0048]. Oxidative stress or damage such as protein oxidation, lipid oxidation, DNA oxidation, and glycoxidation is closely associated with the AD development [@bib0049]. The antioxidant effect of Lf could be explained as Lf restrains membrane lipid peroxidation by scavenging free iron radicals. These iron radicals are cytotoxic activators of lipid peroxidation and oxidative stress. It has been shown that Lf simultaneously enhances antioxidant activity by reducing ROS and enhancing SOD1 and reducing inflammatory markers in AD mice [@bib0045]. In a recent study with AD patients, Lf treatment showed significant improvements in antioxidant and anti-inflammatory markers in serum, and reduced Aβ42 and phosphorylated tau levels, as well as improved cognitive function [@bib0050]. Lf antioxidant activities have also been described in PD experimental models in which this protein was able to prevent oxidative stress and to upregulate the expression of antioxidant enzymes. Simultaneously, the expression of glial markers and proinflammatory cytokines were found reduced [@bib0051], [@bib0052]. Therefore, a boosting effect of Lf may be potentially observed when this protein exerts its antioxidant properties through its iron scavenging abilities and this effect would potentiate the immune response [@bib0053].

In the present study, we report that salivary Lf levels are significantly reduced in AD patients but not in patients with other dementia such as FTD, suggesting a specific Aβ-related link. To our knowledge, this is the first study at examining the relationship between salivary Lf and brain Aβ plaques measured in vivo by amyloid-PET neuroimaging. Amyloid-PET has emerged as a tool for the diagnostic accuracy of prodromal AD, as amyloid deposition occurs years before symptoms onset. MCI encompasses a heterogeneous syndrome with several aetiologies including neurodegenerative diseases, vascular, metabolic or psychiatric illness [@bib0027], [@bib0054]. Inaccuracy of clinicopathological correlation and common coexistence of different pathophysiological processes make difficult in most cases to establish a suitable diagnosis [@bib0027]. Furthermore, MCI without evidence of AD pathophysiology continues to be a mixed and frequently poorly defined group. In our study, Lf showed high variability levels in this group of patients, likely reflecting their biological diversity.

We show that the presence of a positive amyloid-PET signal, that indicates high amyloid plaque load, is highly associated with reduced levels of salivary Lf. These findings support the hypothesis that AD pathophysiology may be related to salivary levels of Lf and the innate immune response to brain infections. Innate immune pathways are commonly activated in other neurodegenerative disorders [@bib0055], [@bib0056], [@bib0057], [@bib0058]. Therefore, it is remarkable that salivary Lf levels will not decrease in other dementia such as FTD. A possible explanation could be that the hypothalamic region, that controls body innate immunity, [@bib0059] is affected in AD [@bib0060], [@bib0061], [@bib0062], [@bib0063], but not in FTD. In addition to amyloid plaques and neurofibrillary tangles, functional studies suggest that hypothalamic dysfunction is a common event in AD, often early in the course of disease [@bib0061]. Although there are evidences indicating that certain hypothalamic regions are also affected in FTD, specifically those that correlate with abnormal eating behaviours [@bib0064], they are different to those affected in AD. The apparently AD-specific salivary Lf reduction may thus not only be useful in the differential diagnosis but could also provide important insights into selective immune vulnerability in neurodegenerative diseases. The secretion of salivary proteins is controlled by cholinergic parasympathetic nerves that release acetylcholine, evoking the secretion of saliva by acinar cells in the salivary gland [@bib0065]. These parasympathetic nerves are connected with the hypothalamus [@bib0060], [@bib0061], [@bib0062], [@bib0063]. We propose that early hypothalamic Aβ accumulation may disrupt hypothalamic function affecting salivary gland regulation that ultimately results in reduced salivary Lf secretion.

In 2011, the NIA-AA guidelines proposed a framework for the use of imaging and CSF biomarkers in the preclinical, MCI and dementia stages of AD \[[@bib0025],[@bib0026],[@bib0066],[@bib0067]\]. However, these current biomarkers used in AD research are expensive or invasive, making difficult or impossible to include them in the routine clinical use in non-specialised health settings. Thus, the present research framework concludes the urgent need for the development of early diagnostic methods, incorporating new biomarkers that can accurately detect and diagnose AD. In recent years, there have been intensified efforts in searching minimum or non-invasive peripheral biomarkers in blood or saliva, for the early diagnosis of AD. Our present work show that salivary Lf levels are decreased in AD and are associated with amyloid-PET imaging profile even in prodromal disease, assuming the multifactorial and heterogeneous aetiology of dementia. The good correlation found in our study between amyloid-PET status and saliva Lf levels suggest that this inexpensive and easy-to-access measurement could be a potential candidate-screening tool in patients with cognitive impairment or suspicion of AD dementia.

In this study, we analysed Lf levels in cohort 1 where patients and control subjects were recruited from regions in Central and South of Spain. Second, the analysis was validated using the cohort 2 composed of donors recruited from Central Spanish region. Our present data demonstrates that the accuracy of salivary Lf as AD biomarker remains in these two separated geographic areas, suggesting that salivary Lf levels can be considered as reproducible biomarker and they may not be affected by other possible influences, including lifestyle and exposure to environmental factors. Other works showed on the contrary, that salivary Lf concentrations might be affected by circadian rhythms and physical activity [@bib0068], [@bib0069], [@bib0070], or environmental and lifestyle factors, including habits like smoking and medication-intake [@bib0071], [@bib0072], [@bib0073]. Therefore, it will be important to replicate these findings in larger-scale prospective and longitudinal studies with other different cohorts even with much more geographic separation. This will allow to accurately analysing the influence of other potential confounding variables.

In conclusion, to our knowledge, this is the first study that assesses the diagnostic performance and specificity of a salivary-based single biomarker to detect prodromal AD and AD dementia based on their amyloid-PET biomarker profile. Importantly, our findings have been replicated in an independent cross-sectional study able to replicate the diagnostic performance of saliva Lf concentration. Finally, this study also proposes that salivary Lf represents one of the main/first lines of defence against pathogens, and that low Lf levels in saliva may represent a reduced protection exacerbating the risk of AD.
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[^1]: Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer\'s disease dementia; FTD, frontotemporal dementia; PET^+^, positive amyloid PET scan; PET^−^, negative amyloid PET scan; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating; Lf, Lactoferrin; NA, not applicable; ns, non-significant. \#*p* value indicates statistical difference within the cohort1

[^2]: \[Bonferroni:

[^3]: *p* \< 0•05 vs. AD-PET^+^.

[^4]: *p* \< 0•01 vs. Control-PET^−^.

[^5]: *p* \< 0•0001 vs. MCI-PET^+^.

[^6]: *p* \< 0•0001 vs. Control-PET^−^.

[^7]: *p* \< 0•01 vs. AD-PET^+^.

[^8]: *p* \< 0•05 vs. Control-PET^−^.

[^9]: *p* \< 0•0001 vs. FTD-PET^−^\].

    Note: Control-PET^+^ group is not included in statistical analysis.

[^10]: Abbreviations: MCI, mild cognitive impairment; PET^+^, positive amyloid PET scan; PET^−^, negative amyloid PET scan; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating; Lf, Lactoferrin; NA, not applicable; ns, non-significant. \#*P* value indicates statistical difference within the cohort 2.

[^11]: \[Bonferroni:

[^12]: *p* \< 0•05 vs. Control-PET^−^.

[^13]: *p* \< 0•01 vs. Control-PET^−^.

[^14]: *p* \< 0•0001 vs. Control-PET-.

[^15]: *p* \< 0•0001 vs. MCI-PET^+^\].

    Note: Control-PET^+^group is not included in statistical analysis.

[^16]: Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer\'s disease dementia; FTD, frontotemporal dementia; PET+, positive amyloid PET scan; PET-, negative amyloid PET scan; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating.

[^17]: \[Spearman:

[^18]: *p* \< 0•0001.

[^19]: *p* \< 0•01\].

[^20]: Performance of salivary Lf analysed by receiver operating characteristic (ROC) curve, corresponding to the discovery data set (cohort 1, left) and the validation data set (cohort 2, right). The optimal cut-off point to differentiate patients with AD from healthy controls from the cohort 1 was used to calculate sensibilities and specificities against the other groups analysed. This optimal cut-off point was determined by the Youden\'s index. Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer\'s disease dementia; FTD, frontotemporal dementia; PET^+^, positive amyloid PET scan; PET^−^, negative amyloid PET scan; AUC: area under the ROC curve; Lf, Lactoferrin.
